New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications
Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...
www.hks.harvard.edu15d
The Pathology of US Health Care—The Example of Weight Loss Medications
August 15, 2024, Paper: "Glucagon-like peptide 1 (GLP-1) receptor agonists and dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonists are among the most promising medical innovations of the ...
verywellhealth23d
NSAIDs and Peptic Ulcer Risk
Why NSAIDs Can Cause Ulcers NSAIDs can cause ulcers by interfering with the stomach's ability to protect itself from gastric acids. While these acids are vital to the digestive process, they can cause ...
beckerspayer24d
The first state to cover Ozempic under the ACA
As of Jan. 1, individual ACA plans and small-group plans from employers in the state include coverage for GLP-1s and gastric inhibitory polypeptide drugs, according to the North Dakota Insurance ...
inforum28d
North Dakota becomes 1st state to cover weight loss medication with federally backed health insurance
and gastric inhibitory polypeptide drugs as of Wednesday, Jan. 1. The drugs can be used to prevent diabetes and to treat insulin resistance, metabolic syndrome or morbid obesity, according to a ...
C&EN1mon
Rigid, α-Helical Polypeptide Nanoprobes with Thermally Activated Delayed Fluorescence for Time-Resolved, High-Contrast Bioimaging
Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou 215123, China ...